Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 367

1.

Stein-like estimators for causal mediation analysis in randomized trials.

Ginestet CE, Emsley R, Landau S.

Stat Methods Med Res. 2019 Jun 7:962280219852388. doi: 10.1177/0962280219852388. [Epub ahead of print]

PMID:
31172884
2.

Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study.

Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E, Badoglio M, Polge E, Labopin M, Gribben J, Pockley AG, Foulds GA, Lobo A, Travis S, Parkes M, Satsangi J, Papaioannou D, Lindsay JO; Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP).

BMC Gastroenterol. 2019 May 31;19(1):82. doi: 10.1186/s12876-019-0992-2.

3.

10Kin1day: A Bottom-Up Neuroimaging Initiative.

van den Heuvel MP, Scholtens LH, van der Burgh HK, Agosta F, Alloza C, Arango C, Auyeung B, Baron-Cohen S, Basaia S, Benders MJNL, Beyer F, Booij L, Braun KPJ, Filho GB, Cahn W, Cannon DM, Chaim-Avancini TM, Chan SSM, Chen EYH, Crespo-Facorro B, Crone EA, Dannlowski U, de Zwarte SMC, Dietsche B, Donohoe G, Plessis SD, Durston S, Díaz-Caneja CM, Díaz-Zuluaga AM, Emsley R, Filippi M, Frodl T, Gorges M, Graff B, Grotegerd D, Gąsecki D, Hall JM, Holleran L, Holt R, Hopman HJ, Jansen A, Janssen J, Jodzio K, Jäncke L, Kaleda VG, Kassubek J, Masouleh SK, Kircher T, Koevoets MGJC, Kostic VS, Krug A, Lawrie SM, Lebedeva IS, Lee EHM, Lett TA, Lewis SJG, Liem F, Lombardo MV, Lopez-Jaramillo C, Margulies DS, Markett S, Marques P, Martínez-Zalacaín I, McDonald C, McIntosh AM, McPhilemy G, Meinert SL, Menchón JM, Montag C, Moreira PS, Morgado P, Mothersill DO, Mérillat S, Müller HP, Nabulsi L, Najt P, Narkiewicz K, Naumczyk P, Oranje B, Ortiz-Garcia de la Foz V, Peper JS, Pineda JA, Rasser PE, Redlich R, Repple J, Reuter M, Rosa PGP, Ruigrok ANV, Sabisz A, Schall U, Seedat S, Serpa MH, Skouras S, Soriano-Mas C, Sousa N, Szurowska E, Tomyshev AS, Tordesillas-Gutierrez D, Valk SL, van den Berg LH, van Erp TGM, van Haren NEM, van Leeuwen JMC, Villringer A, Vinkers CH, Vollmar C, Waller L, Walter H, Whalley HC, Witkowska M, Witte AV, Zanetti MV, Zhang R, de Lange SC.

Front Neurol. 2019 May 9;10:425. doi: 10.3389/fneur.2019.00425. eCollection 2019.

4.

Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus.

Wright AK, Kontopantelis E, Emsley R, Buchan I, Mamas MA, Sattar N, Ashcroft DM, Rutter MK.

Circulation. 2019 Jun 11;139(24):2742-2753. doi: 10.1161/CIRCULATIONAHA.118.039100. Epub 2019 Apr 15.

PMID:
30986362
5.

Feasibility of using a smartphone app to assess early signs, basic symptoms and psychotic symptoms over six months: A preliminary report.

Eisner E, Bucci S, Berry N, Emsley R, Barrowclough C, Drake RJ.

Schizophr Res. 2019 Jun;208:105-113. doi: 10.1016/j.schres.2019.04.003. Epub 2019 Apr 9.

6.

Development and Long-Term Acceptability of ExPRESS, a Mobile Phone App to Monitor Basic Symptoms and Early Signs of Psychosis Relapse.

Eisner E, Drake RJ, Berry N, Barrowclough C, Emsley R, Machin M, Bucci S.

JMIR Mhealth Uhealth. 2019 Mar 29;7(3):e11568. doi: 10.2196/11568.

7.

Feasibility and acceptability of suicide prevention therapy on acute psychiatric wards: randomised controlled trial.

Haddock G, Pratt D, Gooding PA, Peters S, Emsley R, Evans E, Kelly J, Huggett C, Munro A, Harris K, Davies L, Awenat Y.

BJPsych Open. 2019 Jan;5(1):e14. doi: 10.1192/bjo.2018.85.

8.

Protocol for a multicentre randomised controlled parallel-group trial to compare the effectiveness of remotely delivered cognitive-behavioural and graded exercise interventions with usual care alone to lessen the impact of fatigue in inflammatory rheumatic diseases (LIFT).

Martin KR, Bachmair EM, Aucott L, Dures E, Emsley R, Gray SR, Hewlett S, Kumar V, Lovell K, Macfarlane GJ, MacLennan G, McNamee P, Norrie J, Paul L, Ralston S, Siebert S, Wearden A, White PD, Basu N.

BMJ Open. 2019 Jan 30;9(1):e026793. doi: 10.1136/bmjopen-2018-026793.

9.

Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia.

Luckhoff HK, Kilian S, Olivier MR, Phahladira L, Scheffler F, du Plessis S, Chiliza B, Asmal L, Emsley R.

Metab Brain Dis. 2019 Apr;34(2):469-476. doi: 10.1007/s11011-018-0372-6. Epub 2019 Jan 2.

PMID:
30604027
10.

DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial.

Cook JA, Julious SA, Sones W, Hampson LV, Hewitt C, Berlin JA, Ashby D, Emsley R, Fergusson DA, Walters SJ, Wilson ECF, MacLennan G, Stallard N, Rothwell JC, Bland M, Brown L, Ramsay CR, Cook A, Armstrong D, Altman D, Vale LD.

BMJ. 2018 Nov 5;363:k3750. doi: 10.1136/bmj.k3750. No abstract available.

11.

How Inclusive, User-Centered Design Research Can Improve Psychological Therapies for Psychosis: Development of SlowMo.

Hardy A, Wojdecka A, West J, Matthews E, Golby C, Ward T, Lopez ND, Freeman D, Waller H, Kuipers E, Bebbington P, Fowler D, Emsley R, Dunn G, Garety P.

JMIR Ment Health. 2018 Dec 5;5(4):e11222. doi: 10.2196/11222.

12.

Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months.

Luckhoff H, Phahladira L, Scheffler F, Asmal L, du Plessis S, Chiliza B, Kilian S, Emsley R.

Schizophr Res. 2019 Apr;206:171-176. doi: 10.1016/j.schres.2018.11.031. Epub 2018 Nov 30.

PMID:
30503765
13.

DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial.

Cook JA, Julious SA, Sones W, Hampson LV, Hewitt C, Berlin JA, Ashby D, Emsley R, Fergusson DA, Walters SJ, Wilson ECF, Maclennan G, Stallard N, Rothwell JC, Bland M, Brown L, Ramsay CR, Cook A, Armstrong D, Altman D, Vale LD.

Trials. 2018 Nov 5;19(1):606. doi: 10.1186/s13063-018-2884-0.

14.

Changes in insight over the first 24 months of treatment in schizophrenia spectrum disorders.

Phahladira L, Asmal L, Kilian S, Chiliza B, Scheffler F, Luckhoff HK, du Plessis S, Emsley R.

Schizophr Res. 2019 Apr;206:394-399. doi: 10.1016/j.schres.2018.10.013. Epub 2018 Oct 29.

PMID:
30385130
15.

Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA2 guidance.

Sones W, Julious SA, Rothwell JC, Ramsay CR, Hampson LV, Emsley R, Walters SJ, Hewitt C, Bland M, Fergusson DA, Berlin JA, Altman D, Vale LD, Cook JA.

Trials. 2018 Oct 10;19(1):542. doi: 10.1186/s13063-018-2887-x.

16.

Effect of Digital Cognitive Behavioral Therapy for Insomnia on Health, Psychological Well-being, and Sleep-Related Quality of Life: A Randomized Clinical Trial.

Espie CA, Emsley R, Kyle SD, Gordon C, Drake CL, Siriwardena AN, Cape J, Ong JC, Sheaves B, Foster R, Freeman D, Costa-Font J, Marsden A, Luik AI.

JAMA Psychiatry. 2018 Sep 25. doi: 10.1001/jamapsychiatry.2018.2745. [Epub ahead of print]

PMID:
30264137
17.

Cognitive-perceptual deficits and symptom correlates in first-episode schizophrenia.

Olivier RM, Kilian S, Chiliza B, Asmal L, Oosthuizen PP, Emsley R, Kidd M.

S Afr J Psychiatr. 2017 Aug 31;23:1049. doi: 10.4102/sajpsychiatry.v23i0.1049. eCollection 2017.

18.

Suicide and all-cause mortality following routine hospital management of self-harm: Propensity score analysis using multicentre cohort data.

Steeg S, Carr M, Emsley R, Hawton K, Waters K, Bickley H, Ness J, Geulayov G, Kapur N.

PLoS One. 2018 Sep 27;13(9):e0204670. doi: 10.1371/journal.pone.0204670. eCollection 2018.

19.

Paediatric Autism Communication Therapy-Generalised (PACT-G) against treatment as usual for reducing symptom severity in young children with autism spectrum disorder: study protocol for a randomised controlled trial.

Green J, Aldred C, Charman T, Le Couteur A, Emsley RA, Grahame V, Howlin P, Humphrey N, Leadbitter K, McConachie H, Parr JR, Pickles A, Slonims V, Taylor C; PACT-G Group.

Trials. 2018 Sep 21;19(1):514. doi: 10.1186/s13063-018-2881-3.

20.

Correction to: Enhancing maternal and infant wellbeing: study protocol for a feasibility trial of the Baby Triple P Positive Parenting programme for mothers with severe mental health difficulties (the IMAGINE study).

Wittkowski A, Cartwright K, Emsley R, Bee P, Camacho E, Calam R, Cross C, Abel KM, Reid H.

Trials. 2018 Sep 21;19(1):516. doi: 10.1186/s13063-018-2918-7.

21.

Social media and its relationship with mood, self-esteem and paranoia in psychosis.

Berry N, Emsley R, Lobban F, Bucci S.

Acta Psychiatr Scand. 2018 Dec;138(6):558-570. doi: 10.1111/acps.12953. Epub 2018 Sep 10.

22.
23.

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study.

Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, Reynolds NJ, Stocken D, Emsley R, Griffiths CEM, Smith C; PSORT Consortium and on behalf of the BADBIR Study Group.

Br J Dermatol. 2019 May;180(5):1069-1076. doi: 10.1111/bjd.16776. Epub 2018 Aug 28.

24.

Method of levels therapy for first-episode psychosis: rationale, design and baseline data for the feasibility randomised controlled Next Level study.

Griffiths R, Mansell W, Carey TA, Edge D, Emsley R, Tai SJ.

BJPsych Open. 2018 Aug 14;4(5):339-345. doi: 10.1192/bjo.2018.44. eCollection 2018 Sep.

25.

The Feasibility and Effectiveness of PASS Plus, A Lay Health Worker Delivered Comprehensive Intervention for Autism Spectrum Disorders: Pilot RCT in a Rural Low and Middle Income Country Setting.

Divan G, Vajaratkar V, Cardozo P, Huzurbazar S, Verma M, Howarth E, Emsley R, Taylor C, Patel V, Green J.

Autism Res. 2019 Feb;12(2):328-339. doi: 10.1002/aur.1978. Epub 2018 Aug 10.

PMID:
30095230
26.

The expression of neurological soft signs in two African populations with first-episode schizophrenia.

Ojagbemi A, Chiliza B, Bello T, Asmal L, Esan O, Emsley R, Gureje O.

Transcult Psychiatry. 2018 Oct;55(5):669-688. doi: 10.1177/1363461518786167. Epub 2018 Jul 25.

PMID:
30044188
27.

Variation within voltage-gated calcium channel genes and antipsychotic treatment response in a South African first episode schizophrenia cohort.

O'Connell KS, McGregor NW, Malhotra A, Lencz T, Emsley R, Warnich L.

Pharmacogenomics J. 2019 Feb;19(1):109-114. doi: 10.1038/s41397-018-0033-5. Epub 2018 Jul 22.

PMID:
30032160
28.

Cognitive Behavioral Therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?

Spencer HM, McMenamin M, Emsley R, Turkington D, Dunn G, Morrison AP, Brabban A, Hutton P, Dudley R.

Schizophr Res. 2018 Dec;202:385-386. doi: 10.1016/j.schres.2018.07.016. Epub 2018 Jul 13.

PMID:
30017459
29.

Exploring the relationship between the anticipation and experience of pleasure in people with schizophrenia: An experience sampling study.

Edwards CJ, Cella M, Emsley R, Tarrier N, Wykes THM.

Schizophr Res. 2018 Dec;202:72-79. doi: 10.1016/j.schres.2018.06.040. Epub 2018 Jul 7.

30.

Efficacy of Tianeptine 25-50 mg in Elderly Patients With Recurrent Major Depressive Disorder: An 8-Week Placebo- and Escitalopram-Controlled Study.

Emsley R, Ahokas A, Suarez A, Marinescu D, Dóci I, Lehtmets A, Milanova V, Lee MS, Didi R, Araszkiewicz A, Sulaiman AH, Blanchot FP, Crutel VS, Antoine C, Penelaud PF.

J Clin Psychiatry. 2018 Jul 3;79(4). pii: 17m11741. doi: 10.4088/JCP.17m11741.

31.

Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence: A Post Hoc Analysis of a Randomized Placebo-Controlled Study.

Emsley R, Nuamah I, Gopal S, Hough D, Fleischhacker WW.

J Clin Psychiatry. 2018 Jun 19;79(4). pii: 17m11874. doi: 10.4088/JCP.17m11874.

32.

Examining the Factor Structure and Psychometric Properties of a Guilt Management Scale (GMS).

McIvor K, Degnan A, Pugh L, Bettney L, Emsley R, Berry K.

Behav Cogn Psychother. 2019 Mar;47(2):181-199. doi: 10.1017/S1352465818000292. Epub 2018 Jun 19.

PMID:
29916337
33.

Associations of intention to undertake physical activity among community dwelling British South Asian adults aged 60 years and over: a cross-sectional study.

Horne M, Emsley R, Woodham A, Wearden A, Skelton DA.

Public Health. 2018 Sep;162:1-8. doi: 10.1016/j.puhe.2018.05.005. Epub 2018 Jun 15.

PMID:
29913349
35.

Factors associated with poor satisfaction with treatment and trial discontinuation in chronic schizophrenia.

Schoemaker JH, Vingerhoets AJJM, Emsley RA.

CNS Spectr. 2018 Jun 5:1-10. doi: 10.1017/S109285291700044X. [Epub ahead of print]

PMID:
29866212
36.

Childhood Trauma Associated White Matter Abnormalities in First-Episode Schizophrenia.

Asmal L, Kilian S, du Plessis S, Scheffler F, Chiliza B, Fouche JP, Seedat S, Dazzan P, Emsley R.

Schizophr Bull. 2019 Mar 7;45(2):369-376. doi: 10.1093/schbul/sby062.

PMID:
29860345
37.

Digital interventions in severe mental health problems: lessons from the Actissist development and trial.

Bucci S, Lewis S, Ainsworth J, Haddock G, Machin M, Berry K, Berry N, Edge D, Emsley R.

World Psychiatry. 2018 Jun;17(2):230-231. doi: 10.1002/wps.20535. No abstract available.

38.

Antipsychotic maintenance treatment in schizophrenia and the importance of preventing relapse.

Emsley R.

World Psychiatry. 2018 Jun;17(2):168-169. doi: 10.1002/wps.20521. No abstract available.

39.

Neurological Soft Signs, Spontaneous and Treatment Emergent Extrapyramidal Syndromes in Black Africans With First Episode Schizophrenia.

Ojagbemi A, Chiliza B, Bello T, Asmal L, Esan O, Emsley R, Gureje O.

Front Psychiatry. 2018 May 1;9:172. doi: 10.3389/fpsyt.2018.00172. eCollection 2018.

40.

Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.

Morrison AP, Law H, Carter L, Sellers R, Emsley R, Pyle M, French P, Shiers D, Yung AR, Murphy EK, Holden N, Steele A, Bowe SE, Palmier-Claus J, Brooks V, Byrne R, Davies L, Haddad PM.

Lancet Psychiatry. 2018 May;5(5):411-423. doi: 10.1016/S2215-0366(18)30096-8. Epub 2018 Apr 5. Erratum in: Lancet Psychiatry. 2019 May 17;:.

41.

Actissist: Proof-of-Concept Trial of a Theory-Driven Digital Intervention for Psychosis.

Bucci S, Barrowclough C, Ainsworth J, Machin M, Morris R, Berry K, Emsley R, Lewis S, Edge D, Buchan I, Haddock G.

Schizophr Bull. 2018 Aug 20;44(5):1070-1080. doi: 10.1093/schbul/sby032. Erratum in: Schizophr Bull. 2018 Jun 6;44(4):933.

42.
43.

Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders.

Scheffler F, Kilian S, Chiliza B, Asmal L, Phahladira L, du Plessis S, Kidd M, Murray RM, Di Forti M, Seedat S, Emsley R.

Schizophr Res. 2018 Sep;199:90-95. doi: 10.1016/j.schres.2018.02.050. Epub 2018 Mar 6.

PMID:
29519756
44.

The genetic architecture of schizophrenia, bipolar disorder, obsessive-compulsive disorder and autism spectrum disorder.

O'Connell KS, McGregor NW, Lochner C, Emsley R, Warnich L.

Mol Cell Neurosci. 2018 Apr;88:300-307. doi: 10.1016/j.mcn.2018.02.010. Epub 2018 Mar 2.

PMID:
29505902
45.

Assessing the subjective experience of participating in a clinical trial (AVATAR).

Hall J, Rus-Calafell M, Omari-Asor L, Ward T, Emsley R, Garety P, Craig TKJ.

Psychiatry Res. 2018 May;263:82-87. doi: 10.1016/j.psychres.2018.02.026. Epub 2018 Feb 13.

PMID:
29502043
46.

Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA).

Stivaros S, Garg S, Tziraki M, Cai Y, Thomas O, Mellor J, Morris AA, Jim C, Szumanska-Ryt K, Parkes LM, Haroon HA, Montaldi D, Webb N, Keane J, Castellanos FX, Silva AJ, Huson S, Williams S, Gareth Evans D, Emsley R, Green J; SANTA Consortium.

Mol Autism. 2018 Feb 22;9:12. doi: 10.1186/s13229-018-0190-z. eCollection 2018.

47.

Modification of the association between antipsychotic treatment response and childhood adversity by MMP9 gene variants in a first-episode schizophrenia cohort.

McGregor N, Thompson N, O'Connell KS, Emsley R, van der Merwe L, Warnich L.

Psychiatry Res. 2018 Apr;262:141-148. doi: 10.1016/j.psychres.2018.01.044. Epub 2018 Feb 7.

PMID:
29448178
48.

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review.

Emsley R, Kilian S.

Neuropsychiatr Dis Treat. 2018 Jan 5;14:205-223. doi: 10.2147/NDT.S139633. eCollection 2018. Review.

49.

Reward processing dysfunction in ventral striatum and orbitofrontal cortex in Parkinson's disease.

du Plessis S, Bossert M, Vink M, van den Heuvel L, Bardien S, Emsley R, Buckle C, Seedat S, Carr J.

Parkinsonism Relat Disord. 2018 Mar;48:82-88. doi: 10.1016/j.parkreldis.2017.12.024. Epub 2017 Dec 24.

PMID:
29307561
50.

The effectiveness of the Older prisoner Health and Social Care Assessment and Plan (OHSCAP): a randomised controlled trial.

Forsyth K, Archer-Power L, Senior J, Meacock R, Webb R, Emsley R, Edge D, Walsh E, Ware S, Challis D, Hayes A, O’Hara K, Burns A, Shaw J.

Southampton (UK): NIHR Journals Library; 2017 Dec.

Supplemental Content

Loading ...
Support Center